Study of Blood Samples in Patients With Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00959556
Recruitment Status : Unknown
Verified August 2009 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : August 14, 2009
Last Update Posted : January 10, 2011
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to chemotherapy.

PURPOSE: This clinical trial is studying blood samples in patients with breast cancer.

Condition or disease Intervention/treatment
Breast Cancer Other: laboratory biomarker analysis

Detailed Description:


  • Identify constitutional gene variants associated with a change in response.

OUTLINE: Blood samples are collected periodically for analysis of genetic factors.

Study Type : Observational
Estimated Enrollment : 900 participants
Official Title: Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting
Study Start Date : November 2007
Estimated Primary Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Primary Outcome Measures :
  1. Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed breast carcinoma
  • Received first-line chemotherapy (in neoadjuvant or metastatic setting) comprising anthracyclines and/or taxanes, including for a second primary cancer
  • Patient agrees to conservative surgery
  • Hormone receptor status not specified


  • Menopausal status not specified
  • No contraindication for chemotherapy comprising anthracyclines and/or taxanes


  • See Disease Characteristics
  • No prior adjuvant therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00959556

Centre Oscar Lambret Recruiting
Lille, France, 59020
Contact: Jacques Bonneterre, MD, PhD    33-3-20-29-5959   
Sponsors and Collaborators
Centre Oscar Lambret
Principal Investigator: Jacques Bonneterre, MD, PhD Centre Oscar Lambret Identifier: NCT00959556     History of Changes
Other Study ID Numbers: CDR0000633531
First Posted: August 14, 2009    Key Record Dates
Last Update Posted: January 10, 2011
Last Verified: August 2009

Keywords provided by National Cancer Institute (NCI):
recurrent breast cancer
stage IA breast cancer
stage IB breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases